Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae824 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Deborah P Merke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Hydrocortisone, Aromatase Inhibitors, Body Height, Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Context
Height outcome in patients with classic congenital adrenal hyperplasia (CAH) is suboptimal due to glucocorticoid and androgen excess.
Methods
In an open, randomized, controlled trial, children with classic CAH were randomized to receive a combination regimen of antiandrogen, aromatase inhibitor, reduced hydrocortisone, and fludrocortisone prior to puberty or standard therapy (hydrocortisone, fludrocortisone). Females continued on antiandrogen during puberty. The primary endpoint was adult height.
Results
Of 62 children randomized, 45 completed the study. Adult height SDS did not differ between the investigational and control groups (−0.34 [0.93] vs −0.60 [0.89], respectively), mean difference 0.26 [95% CI −0.29, 0.82], P = .35), irrespective of midparental height, but was greater than the predicted adult height pretreatment in both groups (P < .001). Growth rate and rate of bone maturation were reduced in the investigational group prior to puberty, despite lower hydrocortisone dose (7.6 [1.5] vs 15.0 [3.6] mg/m2/day, P < .001), and improvement in predicted adult height appeared greater at pubertal onset (P = .049) compared to standard therapy. Antiandrogen treatment during puberty in girls allowed for lower-dose glucocorticoid, and improved height outcome (adult minus midparental height: −0.7 [4.6] vs −5.6 [5.2] cm, mean difference 4.9 [95% CI 0.09, 9.7], P = .046). Those who received GnRHa had lower growth rate (P = .023) and longer years of unchanged bone age (P = .017), regardless of treatment.
Conclusion
Prepubertal antiandrogen, aromatase inhibitor combination with reduced hydrocortisone improves short-term predicted height for children with CAH but does not result in taller adult stature than those treated with standard therapy, and is not recommended. Females may benefit from antiandrogen treatment during puberty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA.
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Deborah P Merke, Ashwini Mallappa, Margaret F Keil, Gordon B Cutler, Ninet Sinaii
Förderung
- National Institute of Child Health and Human Development
Zitieren
APA
Merke, D. P., Mallappa, A., Parker, M., Sukin, C., Kulkarni, S. E., Keil, M. F., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Cutler, G. B., & Sinaii, N. (2025). Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae824
Vancouver
Merke DP, Mallappa A, Parker M, Sukin C, Kulkarni SE, Keil MF, et al. Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae824
BibTeX
@article{Merke2025,
author = {Merke, Deborah P and Mallappa, Ashwini and Parker, Megan and Sukin, Charles and Kulkarni, Sarah E and Keil, Margaret F and Van Ryzin, Carol and Hill, Suvimol Chirathivat and Reynolds, James C and Cutler, Gordon B and Sinaii, Ninet},
title = {Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae824}
}
EUVIMED